Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19 | NEJM Clinical trials of treatments for coronavirus disease 2019 (Covid-19) have not shown a significant benefit of postexposure prophylaxis. We conducted a phase 2–3 double-blind trial to assess the eff...

postexposure prophylaxis with #Paxlovix for 5 or 10 days did not significantly reduce the risk of symptomatic #Covid infection

www.nejm.org/doi/full/10....

#MedSky🧪#IdSky #Publichealth #Viralimmunology @nejm A phase 2–3 double-blind trial to assess the efficacy and safety of #Paxlovix in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact with #COVID19 within 96 hours before randomization.